Dr Lal PathLabs Completes Full Acquisition of Centrapath Labs

Dr Lal PathLabs Ltd, a prominent name in India's diagnostic services sector, has finalized the purchase of the remaining 30 percent stake in Centrapath Labs Pvt Ltd. This move, executed through its subsidiary PathLabs Unifiers Pvt Ltd (PUPL), now establishes Centrapath Labs as a wholly owned subsidiary within the Dr Lal PathLabs group, according to an official regulatory filing released on October 13, 2026.

Centrapath Labs, founded in July 2019 and headquartered in Indore, Madhya Pradesh, specializes in healthcare and diagnostic services. Over the past three fiscal years, the company has shown steady business activity, with reported revenues of Rs 20.8 crore in FY24, Rs 23.7 crore in FY25, and Rs 20.5 crore in FY26. The acquisition price was set at Rs 1,608.35 per share for the residual 30 percent equity, reflecting Dr Lal PathLabs’ commitment to consolidating its presence in the diagnostics market.

Dr Lal PathLabs, established in 1949, has built a reputation as one of India’s leading diagnostic service providers, operating a large network of labs and collection centers across the country. The company offers a broad range of diagnostic tests, from basic blood work to advanced molecular diagnostics. Its recent acquisition of full ownership in Centrapath Labs aligns with a broader strategy to expand its footprint in regional markets and enhance operational integration.

Centrapath Labs’ location in Indore positions it strategically within the central Indian healthcare ecosystem, an area witnessing growing demand for quality diagnostic services. By bringing Centrapath Labs entirely under its control, Dr Lal PathLabs is likely aiming to streamline service offerings, improve quality control, and leverage centralized management to boost efficiency.

The acquisition also highlights ongoing consolidation trends in India’s healthcare diagnostics sector, where larger players are increasingly acquiring smaller regional labs to extend their reach and standardize care. This integration facilitates better resource utilization and investment in technology upgrades, which are necessary to meet rising patient expectations and regulatory standards.

PathLabs Unifiers Pvt Ltd, the subsidiary responsible for this transaction, functions as Dr Lal PathLabs’ vehicle for managing investments and operations in associated entities. By making Centrapath Labs a step-down subsidiary, Dr Lal PathLabs can maintain direct oversight of the company’s strategic direction while benefiting from localized market knowledge and operational expertise.

The deal was concluded at a time when the healthcare diagnostics sector in India continues to grow, driven by increasing health awareness, rising income levels, and expanding insurance coverage. Investments like this acquisition support Dr Lal PathLabs’ ambition to remain competitive and responsive to evolving market demands.

With this acquisition, Dr Lal PathLabs not only enhances its service network but also reinforces its position as a key player in the diagnostics industry, ensuring better accessibility and quality of healthcare services for patients in Madhya Pradesh and beyond.